A new path for CF clinical trials through the use of historical controls.

Autor: Magaret AS; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Hospital, Seattle, WA, United States of America; Department of Pediatrics, University of Washington, Seattle, WA, United States of America; Department of Biostatistics, University of Washington, Seattle, WA, United States of America. Electronic address: amalia.magaret@seattlechildrens.org., Warden M; Department of Epidemiology, University of Washington, Seattle, WA, United States of America., Simon N; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Hospital, Seattle, WA, United States of America; Department of Biostatistics, University of Washington, Seattle, WA, United States of America., Heltshe S; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Hospital, Seattle, WA, United States of America; Department of Pediatrics, University of Washington, Seattle, WA, United States of America., Retsch-Bogart GZ; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America., Ramsey BW; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Hospital, Seattle, WA, United States of America; Department of Pediatrics, University of Washington, Seattle, WA, United States of America., Mayer-Hamblett N; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Hospital, Seattle, WA, United States of America; Department of Pediatrics, University of Washington, Seattle, WA, United States of America; Department of Biostatistics, University of Washington, Seattle, WA, United States of America.

Publikováno v: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2022 Mar; Vol. 21 (2), pp. 293-299. Date of Electronic Publication: 2021 Dec 05.

Building global development strategies for cf therapeutics during a transitional cftr modulator era.

Autor: Mayer-Hamblett N; University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA. Electronic address: nicole.hamblett@seattlechildrens.org., van Koningsbruggen-Rietschel S; Cystic Fibrosis Center, Children's Hospital, University of Cologne; Faculty of Medicine and University Hospital Cologne, Cologne Germany., Nichols DP; University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA., VanDevanter DR; Case Western Reserve University School of Medicine, Cleveland, OH., Davies JC; National Heart & Lung Institute, Imperial College London, London, UK; Royal Brompton & Harefield NHS Foundation Trust, London, UK., Lee T; Leeds Regional Paediatric Cystic Fibrosis Centre, Leeds, UK., Durmowicz AG; Cystic Fibrosis Foundation, Bethesda, MD., Ratjen F; University of Toronto, Toronto, Canada., Konstan MW; Case Western Reserve University School of Medicine, Cleveland, OH; Rainbow Babies and Children's Hospital, Cleveland, OH., Pearson K; Seattle Children's Hospital, Seattle, WA., Bell SC; Children's Health Research Centre, The University of Queensland, Brisbane, Australia., Clancy JP; Cystic Fibrosis Foundation, Bethesda, MD., Taylor-Cousar JL; National Jewish Health, Denver, CO., De Boeck K; University of Leuven, Leuven, Belgium., Donaldson SH; University of North Carolina at Chapel Hill, Chapel Hill, NC., Downey DG; Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland., Flume PA; Medical University of South Carolina, Charleston, SC., Drevinek P; Charles University, Prague, Czechia, Motol University Hospital, Prague, Czechia., Goss CH; University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA., Fajac I; Université de Paris, Paris, France., Magaret AS; University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA., Quon BS; University of British Columbia, Vancouver, British Columbia., Singleton SM; Cystic Fibrosis Foundation, Bethesda, MD., VanDalfsen JM; Seattle Children's Hospital, Seattle, WA., Retsch-Bogart GZ; University of North Carolina at Chapel Hill, Chapel Hill, NC.

Publikováno v: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2020 Sep; Vol. 19 (5), pp. 677-687. Date of Electronic Publication: 2020 Jun 07.

Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis.

Autor: McKinzie CJ; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, United States. Electronic address: cameron.mckinzie@unchealth.unc.edu., Goralski JL; Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Noah TL; Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Retsch-Bogart GZ; Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Prieur MB; Department of Psychiatry and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States.

Publikováno v: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2017 Jul; Vol. 16 (4), pp. 525-527. Date of Electronic Publication: 2017 Jun 08.

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.

Autor: Flume PA; Medical University of South Carolina, 96 Jonathan Lucas Street, 812-CSB, Charleston, SC 29425, USA. Electronic address: flumepa@musc.edu., Clancy JP; Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229, USA. Electronic address: John.clancy@cchmc.org., Retsch-Bogart GZ; University of North Carolina at Chapel Hill, Division of Pediatric Pulmonology, 450 MacNider Hall, CB#7217, 333 S. Columbia St., Chapel Hill, NC 27599-7217, USA. Electronic address: gzrb@med.unc.edu., Tullis DE; University of Toronto, Division of Respirology, St Michael's Hospital 6-049, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada. Electronic address: TULLISE@smh.ca., Bresnik M; Gilead Sciences, 333 Lakeside Dr., Foster City, CA 94404, USA. Electronic address: mark.bresnik@gilead.com., Derchak PA; Gilead Sciences, 333 Lakeside Dr., Foster City, CA 94404, USA. Electronic address: alex.derchak@gilead.com., Lewis SA; Gilead Sciences, 199 E. Blaine St., Seattle, WA 98102, USA. Electronic address: sandy.lewis@gilead.com., Ramsey BW; University of Washington, Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA 98105, USA. Electronic address: bonnie.ramsey@seattlechildrens.org.

Publikováno v: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2016 Nov; Vol. 15 (6), pp. 809-815. Date of Electronic Publication: 2016 May 24.

Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)

Autor: Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB

Publikováno v: Journal of Antimicrobial Chemotherapy (JAC); Oct2011, Vol. 66 Issue 10, p2398-2404, 7p